WB;IF;ELISA

45kD

The antiserum was produced against synthesized peptide derived from human GPR109. AA range:285-334

HM74 Polyclonal Antibody detects endogenous levels of HM74 protein.

Polyclonal, Rabbit,IgG

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Western Blot: 1/500 - 1/2000. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/10000. Not yet tested in other applications.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

1 mg/ml

developmental stage:Expression in neutrophils occurs in the late terminal differentiation phase.,function:Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis.,miscellaneous:The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.,similarity:Belongs to the G-protein coupled receptor 1 family.,tissue specificity:Expression largely restricted to adipose tissue and spleen. Expressed on mature neutrophils but not on immature neutrophils or eosinophils.,

developmental stage:Expression in neutrophils occurs in the late terminal differentiation phase.,function:Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis.,miscellaneous:The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-meth

GPR109B

G-protein coupled receptor 109B

HM74

HCAR3; GPR109B; HCA3; HM74B; NIACR2; Hydroxycarboxylic acid receptor 3; G-protein coupled receptor 109B; G-protein coupled receptor HM74; G-protein coupled receptor HM74B; Niacin receptor 2; Nicotinic acid receptor 2; HCAR2; GPR109A; HCA2;

>>cAMP signaling pathway

8843/338442

P49019/Q8TDS4

80885

353250

Q80Z39

Cell membrane; Multi-pass membrane protein.

Expression largely restricted to adipose tissue and spleen.

-20°C/1 year